Altimmune, Inc. (FRA:3G0)

Market Cap	514.50M +13.1%
Revenue (ttm)	17.05K -61.5%
Net Income	-71.52M
EPS	-0.90
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2,261
Open	3.601
Previous Close	3.513
Day's Range	3.601 - 3.601
52-Week Range	2.320 - 8.140
Beta	n/a
RSI	56.28
Earnings Date	Feb 26, 2026

About Altimmune

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 59
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3G0

Financial Performance

In 2024, Altimmune's revenue was $20,000, a decrease of -95.31% compared to the previous year's $426,000. Losses were -$95.06 million, 7.48% more than in 2023.

Financial numbers in USD